Bisacodyl

證據等級: L5

預測適應症: 0 個

Bisacodyl: Drug Repurposing Evaluation Report

One-Sentence Summary

Bisacodyl is a stimulant laxative widely used for the relief of constipation and bowel preparation before medical procedures. The TxGNN model did not generate any predicted new indications for this drug. Combined with multiple critical data gaps (MOA, safety warnings, approved indication text), this candidate cannot proceed to further evaluation at this time.

Quick Overview

Item	Content
Original Indication	Constipation / Bowel preparation (licence text not available in data pack)
Predicted New Indication	None — no predictions generated by TxGNN
TxGNN Prediction Score	N/A
Evidence Level	L5 (No model prediction output, no supporting studies)
Malaysia Market Status	✓ Marketed
Number of Registrations	13
Recommended Decision	Hold

Why Was No Prediction Generated?

Bisacodyl (DrugBank: DB09020) is a diphenylmethane derivative that acts as a stimulant laxative. It works locally on the colonic mucosa by stimulating peristalsis and promoting water and electrolyte accumulation in the intestinal lumen. Its pharmacological action is predominantly local and mechanistically narrow — limited to enhancing bowel motility.

There are several likely reasons the TxGNN knowledge graph did not produce repurposing candidates for Bisacodyl:

Limited systemic pharmacological activity. Bisacodyl acts almost exclusively on the gastrointestinal tract and has minimal systemic absorption. Drugs with narrow, locally-acting mechanisms are less likely to have plausible connections to distant disease nodes in the knowledge graph.
Sparse molecular interaction data. As an over-the-counter laxative with a well-characterised and simple mechanism, Bisacodyl has fewer recorded molecular targets, protein interactions, and pathway connections in databases like DrugBank — resulting in fewer edges in the knowledge graph for the model to traverse.
Missing MOA data in this evidence pack. The MOA field is flagged as a data gap, which may have further limited the model’s ability to identify mechanistic overlaps with other disease indications.

Clinical Trial Evidence

No predicted indication was generated; therefore, no targeted clinical trial search was performed.

Currently no related clinical trials to report for repurposing candidates.

Literature Evidence

No predicted indication was generated; therefore, no targeted literature search was performed.

Currently no related literature to report for repurposing candidates.

Malaysia Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
(not available)	(not available)	(not available)	(not available)

Note: 13 registrations were identified via the NPRA query (queried 2026-03-27), but detailed licence information (authorization numbers, product names, dosage forms, and approved indication text) was not populated in the evidence pack. This data gap should be remediated by re-querying the NPRA database.

Safety Considerations

Please refer to the package insert for safety information.

All safety fields (key warnings, contraindications, and drug-drug interactions) were returned as data gaps or not found. Before any repurposing evaluation can proceed, the following must be obtained:

Package insert warnings and precautions

Contraindication list

Drug-drug interaction profile

Data Gaps Summary

Gap ID	Item	Severity	Impact	Remediation
DG001	TFDA Package Insert Warnings / Contraindications	Blocking	Cannot enter S1 safety preliminary assessment	Download and parse package insert PDF from TFDA website
DG002	Mechanism of Action (MOA)	High	Affects mechanism-relevance analysis	Query DrugBank API
—	Licence details (all 13 registrations)	High	Cannot confirm approved indication text or dosage forms	Re-query NPRA with full field extraction
—	Predicted indications	Critical	No repurposing candidates to evaluate	Verify KG node mapping; confirm Bisacodyl node exists in TxGNN graph

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model did not generate any repurposing predictions for Bisacodyl. In addition, multiple critical data gaps (MOA, safety profile, licence details) remain unresolved. There is no actionable repurposing signal to evaluate at this time.

To proceed, the following is needed:

Confirm that Bisacodyl (DB09020) is correctly mapped as a node in the TxGNN knowledge graph, and verify edge connectivity
Remediate DG001 (Blocking): Obtain package insert warnings and contraindications
Remediate DG002 (High): Retrieve MOA data from DrugBank API
Re-extract full licence details from the NPRA database for all 13 registrations
If the drug node is confirmed in the KG with adequate connectivity, re-run the TxGNN prediction pipeline and reassess

Disclaimer: This report is for research purposes only and does not constitute medical advice. Any drug repurposing candidates must undergo rigorous clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.